ACA
OCUL icon

Aptus Capital Advisors’s Ocular Therapeutix OCUL Stock Holding History

Aptus Capital Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.27M Buy
638,691
+108,912
+21% +$987K 0.04% 322
2026
Q1 		$4.49M Buy
529,779
+29,027
+6% +$277K 0.04% 356
2025
Q4 		$6.08M Buy
500,752
+98,285
+24% +$1.19M 0.04% 301
2025
Q3 		$4.7M Buy
402,467
+17,000
+4% +$203K 0.03% 328
2025
Q2 		$3.58M Buy
385,467
+39,369
+11% +$308K 0.03% 342
2025
Q1 		$2.54M Buy
346,098
+6,348
+2% +$48.8K 0.03% 365
2024
Q4 		$2.9M Buy
339,750
+76,940
+29% +$751K 0.03% 343
2024
Q3 		$2.29M Hold
262,810
– – 0.03% 302
2024
Q2 		$1.8M Buy
+262,810
New +$1.62M 0.03% 307

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aptus Capital Advisors's OCUL Position: Q2 2026 in Review

Aptus Capital Advisors increased its Ocular Therapeutix (OCUL) stake by 21% in Q2 2026, buying an estimated $987K and bringing the position to 638,691 shares worth $6.27M. The position accounts for 0.04% of the portfolio, ranked #322.

Aptus Capital Advisors first reported a position in OCUL in Q2 2024 and has held it in 9 quarters since. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Aptus Capital Advisors held 638,691 shares of Ocular Therapeutix worth $6.27M as of Q2 2026.
  • Aptus Capital Advisors bought 108,912 Ocular Therapeutix shares in Q2 2026, an estimated $987K.
  • Ocular Therapeutix made up 0.04% of Aptus Capital Advisors's portfolio in Q2 2026, its #322 holding.
  • Aptus Capital Advisors first reported a position in Ocular Therapeutix in Q2 2024 and has held it in 9 quarters since.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.